You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東北製藥(000597.SZ):前三季度預盈2400萬元-3000萬元
格隆匯 10-13 18:37

格隆匯10月13日丨東北製藥(000597.SZ)披露2021年前三季度業績預告,預計2021年1-9月實現歸屬於上市公司股東的淨利潤2400萬元-3000萬元,同比增長2856.03%-3595.04%;預計2021年7-9月實現歸屬於上市公司股東的淨利潤爲虧損3038.41萬元-3638.41萬元,上年同期爲虧損5740.09萬元。業績變動原因說明:

1.報告期內,隨着國內疫情得到有效控制,公司積極開展銷售業務,制定差異化的營銷策略,有效提升產品競爭力;同時,公司持續加強企業管理,利用調整結構、技術攻關、工藝優化、降本增效等多方面措施,將精細化管理量化到各個崗位,讓效益在供、產、銷各個環節中充分體現,實現公司的良性發展。

2.去年同期,公司的經營狀況受新型冠狀病毒肺炎疫情的衝擊較爲明顯。疫情期間,各級醫療機構的診療服務及患者就醫均受到影響,藥品終端需求明顯下降;疫情給公司商業推廣等相關工作帶來一定程度的限制。上述因素導致公司的市場銷售活動受阻,市場銷售額下降,歸屬於上市公司股東的淨利潤較低。

3.經初步測算,公司2021年前三季度非經常性損益爲1600萬元左右,預計扣除非經常性損益後淨利潤爲800萬元-1400萬元,同比增長146.00%-330.50%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account